Mayzent

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

Siponimod-aċidu fumariku

Available from:

Novartis Europharm Limited 

ATC code:

L04

INN (International Name):

siponimod

Therapeutic group:

Immunosuppressanti selettivi

Therapeutic area:

L-Isklerożi Multipla, Sklerożi Multipla Li Tirkadi U Tbatti

Therapeutic indications:

Mayzent huwa indikat għall-kura ta ' pazjenti adulti bi sklerożi multipla progressiva sekondarja (SPMS), bil-marda attiva muri mill-irkadar jew l-immaġini tal-karatteristiċi ta'l-attività infjammatorja.

Product summary:

Revision: 10

Authorization status:

Awtorizzat

Authorization date:

2020-01-13

Patient Information leaflet

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
Dan il-prodott mediċinali huwa suġġett għal monitoraġġ
addizzjonali. Dan ser jippermetti
identifikazzjoni ta’ malajr ta’ informazzjoni ġdida dwar
is-sigurtà. Il-professjonisti tal-kura tas-saħħa
huma mitluba jirrappurtaw kwalunkwe reazzjoni avversa suspettata. Ara
sezzjoni 4.8 dwar kif
għandhom jiġu rappurtati reazzjonijiet avversi.
1.
ISEM IL-PRODOTT MEDIĊINALI
_ _
Mayzent 0.25 mg pilloli miksija b’rita
Mayzent 1 mg pilloli miksija b’rita
_ _
Mayzent 2 mg pilloli miksija b’rita
_ _
_ _
_ _
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Mayzent 0.25 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha siponimod fumaric acid ekwivalenti
għal 0.25 mg siponimod.
_Eċċipjent b’effett magħruf _
Kull pillola fiha 59.1 mg lattosju (bħala monoidrat) u 0.092 mg
leċitina tas-soja.
Mayzent 1 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha siponimod fumaric acid ekwivalenti
għal 1 mg siponimod.
_Eċċipjent b’effett magħruf _
Kull pillola fiha 58.3 mg lattosju (bħala monoidrat) u 0.092 mg
leċitina tas-soja.
Mayzent 2 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha siponimod fumaric acid ekwivalenti
għal 2 mg siponimod.
_Eċċipjent b’effett magħruf _
Kull pillola fiha 57.3 mg lattosju (bħala monoidrat) u 0.092 mg
leċitina tas-soja.
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita
Mayzent 0.25 mg pilloli miksija b’rita
Pillola miksija b’rita b’dijametru ta’ madwar 6.1 mm lewn aħmar
mitfi, tonda, bikonvessa, bix-xfar
imċanfra bil-lowgo tal-kumpanija fuq naħa minnhom u “T” fuq
in-naħa l-oħra.
Mayzent 1 mg pilloli miksija b’rita
Pillola miksija b’rita b’dijametru ta’ madwar 6.1 mm lewn abjad
fil-vjola, tonda, bikonvessa, bix-xfar
imċanfra bil-lowgo tal-kumpanija fuq naħa minnhom u “L” fuq
in-naħa l-oħra.
Mayzent 2 mg pilloli miksija b’rita
Pillola miksija b’rita b’dijametru ta’ madwar 6.1 mm lewn isfar
m
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
Dan il-prodott mediċinali huwa suġġett għal monitoraġġ
addizzjonali. Dan ser jippermetti
identifikazzjoni ta’ malajr ta’ informazzjoni ġdida dwar
is-sigurtà. Il-professjonisti tal-kura tas-saħħa
huma mitluba jirrappurtaw kwalunkwe reazzjoni avversa suspettata. Ara
sezzjoni 4.8 dwar kif
għandhom jiġu rappurtati reazzjonijiet avversi.
1.
ISEM IL-PRODOTT MEDIĊINALI
_ _
Mayzent 0.25 mg pilloli miksija b’rita
Mayzent 1 mg pilloli miksija b’rita
_ _
Mayzent 2 mg pilloli miksija b’rita
_ _
_ _
_ _
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Mayzent 0.25 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha siponimod fumaric acid ekwivalenti
għal 0.25 mg siponimod.
_Eċċipjent b’effett magħruf _
Kull pillola fiha 59.1 mg lattosju (bħala monoidrat) u 0.092 mg
leċitina tas-soja.
Mayzent 1 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha siponimod fumaric acid ekwivalenti
għal 1 mg siponimod.
_Eċċipjent b’effett magħruf _
Kull pillola fiha 58.3 mg lattosju (bħala monoidrat) u 0.092 mg
leċitina tas-soja.
Mayzent 2 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha siponimod fumaric acid ekwivalenti
għal 2 mg siponimod.
_Eċċipjent b’effett magħruf _
Kull pillola fiha 57.3 mg lattosju (bħala monoidrat) u 0.092 mg
leċitina tas-soja.
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita
Mayzent 0.25 mg pilloli miksija b’rita
Pillola miksija b’rita b’dijametru ta’ madwar 6.1 mm lewn aħmar
mitfi, tonda, bikonvessa, bix-xfar
imċanfra bil-lowgo tal-kumpanija fuq naħa minnhom u “T” fuq
in-naħa l-oħra.
Mayzent 1 mg pilloli miksija b’rita
Pillola miksija b’rita b’dijametru ta’ madwar 6.1 mm lewn abjad
fil-vjola, tonda, bikonvessa, bix-xfar
imċanfra bil-lowgo tal-kumpanija fuq naħa minnhom u “L” fuq
in-naħa l-oħra.
Mayzent 2 mg pilloli miksija b’rita
Pillola miksija b’rita b’dijametru ta’ madwar 6.1 mm lewn isfar
m
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 16-01-2024
Public Assessment Report Public Assessment Report Bulgarian 21-09-2023
Patient Information leaflet Patient Information leaflet Spanish 16-01-2024
Public Assessment Report Public Assessment Report Spanish 21-09-2023
Patient Information leaflet Patient Information leaflet Czech 16-01-2024
Public Assessment Report Public Assessment Report Czech 21-09-2023
Patient Information leaflet Patient Information leaflet Danish 16-01-2024
Public Assessment Report Public Assessment Report Danish 21-09-2023
Patient Information leaflet Patient Information leaflet German 16-01-2024
Public Assessment Report Public Assessment Report German 21-09-2023
Patient Information leaflet Patient Information leaflet Estonian 16-01-2024
Public Assessment Report Public Assessment Report Estonian 21-09-2023
Patient Information leaflet Patient Information leaflet Greek 16-01-2024
Public Assessment Report Public Assessment Report Greek 21-09-2023
Patient Information leaflet Patient Information leaflet English 16-01-2024
Public Assessment Report Public Assessment Report English 21-09-2023
Patient Information leaflet Patient Information leaflet French 16-01-2024
Public Assessment Report Public Assessment Report French 21-09-2023
Patient Information leaflet Patient Information leaflet Italian 16-01-2024
Public Assessment Report Public Assessment Report Italian 21-09-2023
Patient Information leaflet Patient Information leaflet Latvian 16-01-2024
Public Assessment Report Public Assessment Report Latvian 21-09-2023
Patient Information leaflet Patient Information leaflet Lithuanian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 16-01-2024
Public Assessment Report Public Assessment Report Lithuanian 21-09-2023
Patient Information leaflet Patient Information leaflet Hungarian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 16-01-2024
Public Assessment Report Public Assessment Report Hungarian 21-09-2023
Patient Information leaflet Patient Information leaflet Dutch 16-01-2024
Public Assessment Report Public Assessment Report Dutch 21-09-2023
Patient Information leaflet Patient Information leaflet Polish 16-01-2024
Public Assessment Report Public Assessment Report Polish 21-09-2023
Patient Information leaflet Patient Information leaflet Portuguese 16-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 16-01-2024
Public Assessment Report Public Assessment Report Portuguese 21-09-2023
Patient Information leaflet Patient Information leaflet Romanian 16-01-2024
Public Assessment Report Public Assessment Report Romanian 21-09-2023
Patient Information leaflet Patient Information leaflet Slovak 16-01-2024
Public Assessment Report Public Assessment Report Slovak 21-09-2023
Patient Information leaflet Patient Information leaflet Slovenian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 16-01-2024
Public Assessment Report Public Assessment Report Slovenian 21-09-2023
Patient Information leaflet Patient Information leaflet Finnish 16-01-2024
Public Assessment Report Public Assessment Report Finnish 21-09-2023
Patient Information leaflet Patient Information leaflet Swedish 16-01-2024
Public Assessment Report Public Assessment Report Swedish 21-09-2023
Patient Information leaflet Patient Information leaflet Norwegian 16-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 16-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 16-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 16-01-2024
Patient Information leaflet Patient Information leaflet Croatian 16-01-2024
Public Assessment Report Public Assessment Report Croatian 21-09-2023

Search alerts related to this product

View documents history